Don’t miss the latest from Senti Biosciences!
Subscribe to email alerts for updates on our pipeline, research, and company news: https://t.co/J1hb3wPH5K
$SNTI #Oncology#Leukemia
Our CEO, Tim Lu, highlighted a transformational milestone as positive FDA RMAT feedback advances SENTI-202 toward a potential registrational study in relapsed/refractory AML.
Read more here: https://t.co/5tkghPdzwI
$SNTI #AML#Oncology#CellTherapy
Our Chief Medical Officer, Kanya Rajangam, highlighted strong momentum for SENTI-202, supported by encouraging clinical activity, a favorable safety profile, and advancements in donor selection.
Learn more: https://t.co/5tkghPdzwI
$SNTI
Senti Biosciences Holdings Announces Positive FDA RMAT Meeting on Registrational Clinical and CMC Strategy for SENTI-202 in Relapsed/Refractory AML, Along with Important Efficacy and Durability Updates on the SENTI-202 Clinical Program
https://t.co/5tkghPdzwI
$SNTI
Senti Biosciences Holdings Reports First Quarter 2026 Financial Results and Highlights Advancement of SENTI-202 Program into Pivotal Phase
https://t.co/HgsBCJQVBL
$SNTI #CellTherapy#Oncology#AML
Senti Bio was founded to build a new generation of smarter medicines designed to address complex diseases using novel and unprecedented approaches.
$SNTI #AML#Oncology
This #WorldDNADay, we recognize the power of genetic science in advancing new approaches to cancer treatment.
At Senti Bio, we’re leveraging gene circuits to drive innovation in cell and gene therapy.
$SNTI #Oncology#AML
On #AMLWorldAwarenessDay, we recognize the urgency to advance research and bring forward new therapies. Because behind every diagnosis is a life, a family, and a future.
We acknowledge the importance of continuing to push science forward to create new possibilities for patients.
Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
https://t.co/7VsUR9QB3z
$SNTI #CellTherapy#Oncology#AML
Senti Biosciences Announces Publication in Cell Systems Demonstrating Advanced Logic-Gated CAR Design for Cell Therapies
https://t.co/c0lt9Ab6Cw
$SNTI #CellTherapy#Oncology#AML
Senti Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
https://t.co/JZAZ1sJo6r
$SNTI #CellTherapy#Oncology#AML
Founded to develop a new generation of smarter medicines, Senti Biosciences is advancing innovative approaches to outsmart complex diseases and redefine what’s possible in medicine.
$SNTI #Oncology#AML
Senti Biosciences to Present Clinical and Translational Data on SENTI-202 at the 11th Annual Innate Killer Conference
https://t.co/bdkvNOiVEz
$SNTI #CellTherapy#Oncology#AML
Senti Biosciences is heading to the Leerink Global Healthcare Conference, March 8-11 in Miami Beach, FL!
Join us for our presentation on March 9th from 2:20–2:50 PM as we share updates on our cell engineering platform and pipeline.
Don't Miss It: https://t.co/jGyuoTud0U
$SNTI
Senti Biosciences to Present at Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026, at 2:20 PM ET
https://t.co/xaFBWjaur5
$SNTI #CellTherapy#Oncology#AML
Senti Bio is a clinical-stage company advancing a new generation of cell and gene therapies for patients living with incurable diseases.
$SNTI #Oncology#AML
Senti Biosciences to Present at TD Cowen 46th Annual Health Care Conference on Monday, March 2nd at 3:10 PM ET
https://t.co/rrKpJaW3b5
$SNTI #CellTherapy#Oncology#AML
Senti Bio Participates in Cell & Gene Live Event Highlighting Cutting-Edge Technologies Advancing Cell Therapy Development
https://t.co/08b5fv6sAi
#CellTherapy#Oncology#AML